Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

This study has been completed.
Sponsor:
Collaborator:
Department of Health and Human Services
Information provided by (Responsible Party):
Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier:
NCT01776541
First received: January 20, 2013
Last updated: January 20, 2015
Last verified: January 2015

January 20, 2013
January 20, 2015
January 2013
June 2013   (final data collection date for primary outcome measure)
  • Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. [ Time Frame: Three weeks after 2nd vaccination (day 43) ] [ Designated as safety issue: No ]

    The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.

    CBER criterion for the adult population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or exceeds 70%.

  • Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain. [ Time Frame: Three weeks after 2nd vaccination (day 43) ] [ Designated as safety issue: No ]

    Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.

    Seroconversion is defined as either a) in subjects with a prevaccination HI titer <10, a postvaccination titer ≥40; or b) in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.

    CBER criterion for the adult population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 40%.

  • Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AE), After Any Vaccination. [ Time Frame: From day 1 through day 7 after any vaccination. ] [ Designated as safety issue: No ]
    Safety was assessed using the number of subjects who reported solicited local and systemic AEs following vaccination with either low or high dose of aH5N1c vaccine.
  • Number of Subjects Reporting Unsolicited AEs After Any Vaccination. [ Time Frame: Any unsolicited AEs - day 1 through day 22 after any vaccination. SAEs, NOCDs. medically attended AEs, AESIs, AEs leading to study withdrawal- day 1 to day 387 ] [ Designated as safety issue: No ]
    Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with either low or high dose of aH5N1c vaccine.
  • To select a vaccine dose based on the achievement of CBER criteria for further development [ Time Frame: Day 43 (3 weeks after second vaccination) ] [ Designated as safety issue: No ]
    Seroprotection and Seroconversion rate measured 3 weeks after second dose of vaccine administration
  • Percentage of subjects with solicited local and systemic adverse events [ Time Frame: 7 days post vaccination ] [ Designated as safety issue: Yes ]
  • Percentage of subjects with unsolicited adverse events [ Time Frame: 3 weeks post vaccination ] [ Designated as safety issue: Yes ]
  • Percentage of subjects with serious adverse events, medically attended adverse events, adverse events leading to withdrawal and adverse events of special interest [ Time Frame: Day 1 through Day 732 ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01776541 on ClinicalTrials.gov Archive Site
  • Geometric Mean Ratios Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine. [ Time Frame: Day 1; day 22; day 43 and day 387 ] [ Designated as safety issue: No ]

    Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of postvaccination to prevaccination HI GMTs, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c is reported.

    The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is >2.5 for subjects 18-60 years of age.

  • Percentages Of Subjects With HI Titers ≥40 Against A/H5N1 Strain. [ Time Frame: Day 1, day 22, day 43 and day 387 ] [ Designated as safety issue: No ]

    Immunogenicity was assessed in terms of percentage of subjects achieving HI titers ≥40, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c according to the CHMP criterion.

    European Licensure (CHMP) criterion is met if the percentage of subjects achieving (at day 43) HI titers ≥40 is >70%.

  • Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain. [ Time Frame: Day 22, day 43 and day 387 ] [ Designated as safety issue: No ]

    Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.

    Seroconversion is defined as: a) for subjects with a prevaccination HI titer <10, a postvaccination titer ≥40; or b) for subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.

    The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion (at day 43) is >40%.

  • Achievement of CHMP criteria 3 weeks after after second dose of vaccine administration [ Time Frame: Day 43 ] [ Designated as safety issue: No ]
    Seroprotection, Seroconversion rate and GMRs measured 3 weeks after second dose of vaccine administration
  • Achievement of CBER and CHMP criteria 3 weeks after first dose of vaccine administration [ Time Frame: Day 22 ] [ Designated as safety issue: No ]
    Seroprotection, Seroconversion rate and GMRs measured 3 weeks after first dose of vaccine administration
  • Achievement of CBER and CHMP criteria 3 weeks after booster dose of vaccine administration [ Time Frame: Day 387 ] [ Designated as safety issue: No ]
    Seroprotection, Seroconversion rate and GMRs measured 3 weeks after booster dose of vaccine administration
Not Provided
Not Provided
 
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.
Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Pandemic H5N1 Influenza
Biological: Adjuvanted H5N1 pandemic influenza vaccine
Comparison of two doses of aH5N1c vaccine
  • Experimental: aH5N1c-High Dose
    Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
    Intervention: Biological: Adjuvanted H5N1 pandemic influenza vaccine
  • Experimental: aH5N1c-Low dose
    Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
    Intervention: Biological: Adjuvanted H5N1 pandemic influenza vaccine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
979
May 2014
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy adult subjects 18 to 64 years of age,
  2. Individuals willing to provide written informed consent,
  3. Individuals in good health,
  4. Individuals willing to allow for their serum samples to be stored beyond the study period.

Exclusion Criteria:

  1. Individuals not able to understand and follow study procedures,
  2. History of any significant illness,
  3. History of any chronic medical condition or progressive disease,
  4. Presence of medically significant cancer,
  5. Known or suspected impairment/alteration of immune function,
  6. Presence of any progressive or severe neurologic disorder,
  7. Presence of any bleeding disorders or conditions that prolongs bleeding time,
  8. History of allergy to vaccine components,
  9. Receipt of any other investigational product within 30 days prior to entry into the study,
  10. History of previous H5N1 vaccination,
  11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,
  12. Receipt of any other vaccine within 2 weeks prior to entry into the study
  13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended study vaccination,
  14. Pregnant or breast feeding,
  15. Females of childbearing potential refusing to use acceptable method of birth control,
  16. Body mass index (BMI) ≥ 35 kg/m2,
  17. History of drug or alcohol abuse,
  18. Any planned surgery during study period,
  19. Individuals conducting the study and their immediate family members,
  20. Individuals with behavioral or cognitive impairment or psychiatric diseases.
Both
18 Years to 64 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Thailand
 
NCT01776541
V89_04
No
Not Provided
Not Provided
Novartis Vaccines
Novartis Vaccines
Department of Health and Human Services
Study Chair: Novartis Vaccines and Diagnostics Novartis Vaccines
Novartis
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP